News|Slideshows|August 29, 2025

August Pharmaceutical Industry Movers & Shakers

A monthly roundup of business and people news in the pharmaceutical industry.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

The strategic question facing biopharmaceutical and medical-device executives today is no longer whether to invest in AI, but how to industrialize it. Credit: Stock.Adobe.com/AREE.

Industrializing Machine Learning and Artificial Intelligence in Life Sciences

ByPartha Anbil

May 21st 2026

Pharma M&A Roundup: Gilead Sciences Expands Collaboration with World Health Organization, Johnson & Johnson Enters Collaboration with Department of Health - Abu Dhabi

ByNicholas Jacobus

May 21st 2026

Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report

ByNicholas Jacobus

May 21st 2026

The Implications of GLP-1s Replacing Oncology as the Key Value Driver

ByMike Hollan,Kevin Dondarski

May 21st 2026

Harpreet Singh, MD, chief medical officer at Precision for Medicine and former FDA Oncology Division Director,

What Does the Regulatory Landscape Look Like From the Other Side of FDA?

ByNicholas Jacobus,Harpreet Singh, MD

May 21st 2026

August Pharmaceutical Industry Movers & Shakers

Related Content

Industrializing Machine Learning and Artificial Intelligence in Life Sciences

Pharma M&A Roundup: Gilead Sciences Expands Collaboration with World Health Organization, Johnson & Johnson Enters Collaboration with Department of Health - Abu Dhabi

Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report

The Implications of GLP-1s Replacing Oncology as the Key Value Driver

What Does the Regulatory Landscape Look Like From the Other Side of FDA?

Trending on PharmExec

Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio

The Industry’s Communication and Engagement with FDA

Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration

Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio

The Evolving Relationship Between FDA and Biotech